English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/191365
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity

AuthorsCervantes, Blanca; Arana, Lide; Murillo-Cuesta, Silvia ; Bruno, Marina; Alkorta, Itziar; Varela-Nieto, Isabel
Otic protection
Stearic acid-based solid lipid nanoparticle (SLN)
Issue Date14-Sep-2019
PublisherMultidisciplinary Digital Publishing Institute
CitationJournal of Clinical Medicine 8(9): 1464 (2019)
AbstractCisplatin is a chemotherapeutic agent that causes the irreversible death of auditory sensory cells, leading to hearing loss. Local administration of cytoprotective drugs is a potentially better option co-therapy for cisplatin, but there are strong limitations due to the difficulty of accessing the inner ear. The use of nanocarriers for the efficient delivery of drugs to auditory cells is a novel approach for this problem. Solid lipid nanoparticles (SLNs) are biodegradable and biocompatible nanocarriers with low solubility in aqueous media. We show here that stearic acid-based SLNs have the adequate particle size, polydispersity index and ζ-potential, to be considered optimal nanocarriers for drug delivery. Stearic acid-based SLNs were loaded with the fluorescent probe rhodamine to show that they are efficiently incorporated by auditory HEI-OC1 (House Ear Institute-Organ of Corti 1) cells. SLNs were not ototoxic over a wide dose range. Glucocorticoids are used to decrease cisplatin-induced ototoxicity. Therefore, to test SLNs’ drug delivery efficiency, dexamethasone and hydrocortisone were tested either alone or loaded into SLNs and tested in a cisplatin-induced ototoxicity in vitro assay. Our results indicate that the encapsulation in SLNs increases the protective effect of low doses of hydrocortisone and lengthens the survival of HEI-OC1 cells treated with cisplatin.
Description© 2019 by the authors.
Publisher version (URL)https://doi.org/10.3390/jcm8091464
Appears in Collections:(UBF) Artículos
(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
Cervantes_Solid_Art2019.pdf2,03 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.